Explore the vast range of titles available.

Objective: Our purpose was to measure A beta 1-42, T-tau and P-tau181 in the cerebrospinal fluid (CSF) of patients with posterior cortical atrophy (PCA), a presenile dementia likely to represent a variant of Alzheimer's disease (AD). Methods: CSF samples from 34 subjects including 9 patients with PCA, 11 age-matched patients with AD and 14 age-matched cognitively healthy controls were analyzed using commercially available ELISA kits. Results: The A beta 1-42, T-tau and P-tau181 levels in PCA patients differed significantly (p < 0.02) from those in healthy controls but were indistinguishable from subjects with a clinical diagnosis of AD. Conclusion: High T-tau and P-tau181 and low A beta 1-42 levels in PCA - typically observed in AD - indicate that the underlying pathology of PCA is usually AD. If these findings are replicated in PCA patients with autopsy-confirmed AD neuropathology, PCA patients may be eligible for disease-modifying AD treatments. Copyright [copy 2010 S. Karger AG, Basel

Objective: Our purpose was to measure Aβ 1–42 , T-tau and P-tau 181 in the cerebrospinal fluid (CSF) of patients with posterior cortical atrophy (PCA), a presenile dementia likely to represent a variant of Alzheimer’s disease (AD). Methods: CSF samples from 34 subjects including 9 patients with PCA, 11 age-matched patients with AD and 14 age-matched cognitively healthy controls were analyzed using commercially available ELISA kits. Results: The Aβ 1–42 , T-tau and P-tau 181 levels in PCA patients differed significantly (p < 0.02) from those in healthy controls but were indistinguishable from subjects with a clinical diagnosis of AD. Conclusion: High T-tau and P-tau 181 and low Aβ 1–42 levels in PCA – typically observed in AD – indicate that the underlying pathology of PCA is usually AD. If these findings are replicated in PCA patients with autopsy-confirmed AD neuropathology, PCA patients may be eligible for disease-modifying AD treatments.

Background/Aims: We aimed at characterizing the clinical features of dementia associated with argyrophilic grain disease (AgD). Methods: Relatives or close friends of 24 individuals with autopsy-confirmed AgD and 29 patients with autopsy-confirmed Alzheimer’s disease (AD) were administered a novel Retrospective Dementia Inventory to assess the cognitive, behavioral and affective symptoms of the deceased patients. Results: AgD patients showed less severe impairments in memory, language, attention and executive function than AD patients.Conclusion: Compared to AD patients, individuals suffering from AgD appear to present with comparable deficits in behavior and affect but relatively spared cognitive functioning.

Objective: Our purpose was to measure Aβ1-42, T-tau and P-tau181 in the cerebrospinal fluid (CSF) of patients with posterior cortical atrophy (PCA), a presenile dementia likely to represent a variant of Alzheimer's disease (AD). Methods: CSF samples from 34 subjects including 9 patients with PCA, 11 age-matched patients with AD and 14 age-matched cognitively healthy controls were analyzed using commercially available ELISA kits. Results: The Aβ1-42, T-tau and P-tau181 levels in PCA patients differed significantly (p < 0.02) from those in healthy controls but were indistinguishable from subjects with a clinical diagnosis of AD. Conclusion: High T-tau and P-tau181 and low Aβ1-42 levels in PCA - typically observed in AD - indicate that the underlying pathology of PCA is usually AD. If these findings are replicated in PCA patients with autopsy-confirmed AD neuropathology, PCA patients may be eligible for disease-modifying AD treatments. Copyright © 2010 S. Karger AG, Basel [PUBLICATION ABSTRACT]

Our purpose was to measure Abeta(1-42), T-tau and P-tau(181) in the cerebrospinal fluid (CSF) of patients with posterior cortical atrophy (PCA), a presenile dementia likely to represent a variant of Alzheimer's disease (AD). CSF samples from 34 subjects including 9 patients with PCA, 11 age-matched patients with AD and 14 age-matched cognitively healthy controls were analyzed using commercially available ELISA kits. The Abeta(1-42), T-tau and P-tau(181) levels in PCA patients differed significantly (p < 0.02) from those in healthy controls but were indistinguishable from subjects with a clinical diagnosis of AD. High T-tau and P-tau(181) and low Abeta(1-42) levels in PCA - typically observed in AD - indicate that the underlying pathology of PCA is usually AD. If these findings are replicated in PCA patients with autopsy-confirmed AD neuropathology, PCA patients may be eligible for disease-modifying AD treatments.

Oct. 25, 1994--Beeba's Creations Inc. (NASDAQ:BEBA) Tuesday announced its operating results for the fourth quarter and year ended Aug. 31, 1994. Net sales for the fourth quarter of fiscal 1994 amounted to $30.6 million, or 14.1 percent lower than the $35.6 million reported for the fourth quarter of last year. The company showed a net loss of $102,582, or 4 cents per share, for the current quarter, as compared with net income of $461,720, or 17 cents per share, for the fourth quarter of fiscal 1993. (excerpt)

Beeba's Creations Inc. (NASDAQ/NMS: BEBA) Friday announced sales and net income for the fourth quarter and year ended Aug. 31, 1993. The company also announced that it had declared a regular quarterly dividend of 8 cents per share payable to holders of record as of Nov. 1, 1993. The dividend payment will be made Nov. 30, 1993. Net sales for the fourth quarter of fiscal 1993 amounted to $35.6 million, or 12.5-percent lower than the $40.7 million reported for the fourth quarter of last year. Net income for the current quarter was $461,720, or 17 cents per share, as compared with $1.6 million, or 60 cents per share, for the fourth quarter of fiscal 1992. (excerpt)

Body Drama Inc. (NASDAQ/NMS:BDRM) Friday announced operating results for its fourth quarter and year ended Aug. 31, 1993. Net sales for the fourth quarter increased 20.7 percent to $8.7 milion, vs. $7.2 million for the fourth quarter of last year. The company generated a loss of $604,921, or 19 cents per share, in the fourth quarter of fiscal 1993, compared with net income of $209,380, or 7 cents per share, for the last quarter of fiscal 1992. For the year ended Aug. 31, 1993, net sales were $31.8 million, vs. $28.4 million for the year ended Aug. 31, 1992. The company showed a net loss of $647,466, or 20 cents per share, for the current year, with net income of $1,491,520, or 49 cents per share, for fiscal 1992. (excerpt)

Body Drama Inc. (NASDAQ:BDRM) Wednesday announced operating results for its fourth quarter and year ended Aug. 31, 1992. Net sales for the fourth quarter of fiscal 1992 increased 17 percent to $7.2 million vs. $6.1 million for the fourth quarter of last year. Net income decreased from $232,000 for the fourth quarter of last year to $209,000 for the fourth quarter of fiscal 1992. The current quarter's results include a charge to income of approximately $150,000 for the costs associated with the investigation of an acquisition which was subsequently not consummated. Earnings per share were 7 cents for the current fourth quarter vs. 12 cents for the same quarter last year. (excerpt)

Beeba's Creations Inc. (NASDAQ:BEBA) Wednesday reported that its net sales had increased 21 percent in its fourth quarter ended Aug. 31, 1992, compared with the same quarter last year. Net income for the current quarter increased 53 percent over the year-earlier results. The company also announced that it had declared a regular quarterly dividend of 7 cents per share to holders of record as of Oct. 30, 1992. The dividend payment will be made on Nov. 30, 1992. Net sales for the fourth quarter were $40.7 million, vs. $33.8 million reported for the fourth quarter of last year. Net income for the current quarter increased to $1,606,840, or 60 cents per share, from $1,051,334, or 28 cents per share, for the fourth quarter of fiscal 1991. (excerpt)